Viralytics is focused on the development and commercialisation of oncolytic immunotherapies that harness the power of certain viruses to preferentially infect and kill cancer cells. The lead product candidate is CAVATAKTM, a proprietary formulation of the common cold Coxsackievirus Type A21 (CVA21), now being evaluated in Phase 1 and 2 clinical trials.
|
NEWS: Tagged in Where markets meet medicine; a biotech entrepreneur at the tip of the spear | 14 Feb 2022 |
| Name | Position | Year Started |
|---|---|---|
Chief Executive Officer
|
2013 | |
Non-Executive Chair
|
2007 | |
Non-Executive Director
|
2011 |
| Name | Position | Year Started | Year Ended |
|---|---|---|---|
Non-Executive Director
|
2014 | 2018 | |
Non-Executive Director
|
2008 | 2014 | |
Company Secretary
|
2013 | 2014 | |
Managing Director
|
2005 | 2012 | |
Chief Operating Officer
|
2008 | 2011 |
| Date | Company | Transaction Type | Total Value | |
|---|---|---|---|---|
| Viralytics | Share purchase plan | $3.50m | >> |
